Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. News
Dec 6, 2025 - globenewswire.com
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
Dec 1, 2025 - globenewswire.com
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Nurix Therapeutics, Inc. Quantitative Score
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Nurix Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Nurix Therapeutics, Inc. Financials
Table Compare
Compare NRIX metrics with: | |||
|---|---|---|---|
Earnings & Growth | NRIX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NRIX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NRIX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NRIX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Nurix Therapeutics, Inc. Income
Nurix Therapeutics, Inc. Balance Sheet
Nurix Therapeutics, Inc. Cash Flow
Nurix Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Nurix Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | Chief Executive Officer, President & Director |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary & Chief Compliance Officer |
| Mr. Johannes Van Houte | Chief Financial Officer |
| Mr. Christopher B. Phelps Ph.D. | Senior Vice President & Head of Early Drug Discovery |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | Chief Executive Officer, President & Director | 1962 | 1.06M | |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer | 1971 | 750.51K | |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary & Chief Compliance Officer | 1965 | 733.14K | |
| Mr. Johannes Van Houte | Chief Financial Officer | Male | 1966 | 733.14K |
| Mr. Christopher B. Phelps Ph.D. | Senior Vice President & Head of Early Drug Discovery | Male | -- |
Nurix Therapeutics, Inc. Insider Trades
| Date | 24 Nov |
| Name | Ring Christine |
| Role | Chief Legal Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 37600 |
| Date | 24 Nov |
| Name | Ring Christine |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 37600 |
| Date | 24 Nov |
| Name | Ring Christine |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 37600 |
| Date | 6 Nov |
| Name | DANSEY ROGER D |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 50000 |
| Date | 6 Nov |
| Name | DANSEY ROGER D |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 24 Nov | Ring Christine | Chief Legal Officer | Acquired | M-Exempt | 37600 |
| 24 Nov | Ring Christine | Chief Legal Officer | Disposed | S-Sale | 37600 |
| 24 Nov | Ring Christine | Chief Legal Officer | Disposed | M-Exempt | 37600 |
| 6 Nov | DANSEY ROGER D | Director | Acquired | A-Award | 50000 |
| 6 Nov | DANSEY ROGER D | Director | Disposed | 0 |